The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study.

Faggiano A, Modica R, Severino R, Camera L, Fonti R, Del Prete M, Chiofalo MG, Aria M, Ferolla P, Vitale G, Pezzullo L, Colao A

Endocrine23 Mar 2018Cited by 20 (Europe PMC)

PMID29572709DOI10.1007/s12020-018-1583-7PepBankPUB-29572709

Source link PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialEfficacy outcome
In medullary thyroid cancer patients receiving pasireotide, median progression-free survival was 36 months (95% CI 19.5-52.5).
In plain wordsIn medullary thyroid cancer patients receiving pasireotide, median time without progression was 36 months.
Peptide
Pasireotide
Outcome
Not applicableProgression-free survival
Study
n = 19
Analysis
Primary
Outcome group
Tumor growth · Cancer
Studied dose
60 mg/m · at least 6 monthsAs given in this study (human).
Measurements
Median progression-free survival
36 months
pasireotide LAR
95% CI, median progression-free survival
19.5 to 52.5 months
pasireotide LAR
Source sentences
Summary
Median PFS with pasireotide was 36 months (95% CI: 19.5-52.5).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with progressive metastatic or persistent postoperative MTC received pasireotide LAR 60 mg/m for at least 6 months.
Summary · context
Nineteen consecutive patients were enrolled.
Report a problemFND-2957270901
02HumanNon-randomized trialSafety outcome
In medullary thyroid cancer patients receiving pasireotide, diarrhoea was among the most frequent adverse events, with grade 3 events in 5.3%.
In plain wordsIn medullary thyroid cancer patients receiving pasireotide, diarrhoea was common and grade 3 diarrhoea occurred in 5.3%.
Peptide
Pasireotide
Outcome
Not applicableDiarrhoea
Study
n = 19
Analysis
Secondary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
60 mg/m · at least 6 monthsAs given in this study (human).
Measurements
Grade 3 diarrhoea
5.3%
pasireotide
Source sentences
Summary
Diarrhoea and hyperglycaemia were the most frequent adverse events with pasireotide (grade 3 in 5.3% each).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with progressive metastatic or persistent postoperative MTC received pasireotide LAR 60 mg/m for at least 6 months.
Summary · context
Nineteen consecutive patients were enrolled.
Report a problemFND-2957270903
03HumanNon-randomized trialSafety outcome
In medullary thyroid cancer patients receiving pasireotide, hyperglycaemia was among the most frequent adverse events, with grade 3 events in 5.3%.
In plain wordsIn medullary thyroid cancer patients receiving pasireotide, high blood sugar was common and grade 3 events occurred in 5.3%.
Peptide
Pasireotide
Outcome
Not applicableHyperglycaemia
Study
n = 19
Analysis
Secondary
Outcome group
Adverse events · Metabolic and weight
Studied dose
60 mg/m · at least 6 monthsAs given in this study (human).
Measurements
Grade 3 hyperglycaemia
5.3%
pasireotide
Source sentences
Summary
Diarrhoea and hyperglycaemia were the most frequent adverse events with pasireotide (grade 3 in 5.3% each).
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with progressive metastatic or persistent postoperative MTC received pasireotide LAR 60 mg/m for at least 6 months.
Summary · context
Nineteen consecutive patients were enrolled.
Report a problemFND-2957270904
04HumanNon-randomized trialEfficacy outcome
In medullary thyroid cancer patients receiving pasireotide LAR, nine patients (47%) had tumour progression.
In plain wordsIn medullary thyroid cancer patients receiving pasireotide, nine patients experienced tumour progression.
Peptide
Pasireotide
Outcome
Not applicableTumor progression
Study
n = 19
Outcome group
Tumor growth · Cancer
Studied dose
60 mg/m · at least 6 monthsAs given in this study (human).
Measurements
Patients with tumour progression
9 patients
pasireotide LAR
Share of patients with tumour progression
47%
pasireotide LAR
Source sentences
Summary
Nine patients (47%) had tumour progression
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with progressive metastatic or persistent postoperative MTC received pasireotide LAR 60 mg/m for at least 6 months.
Summary · context
Nineteen consecutive patients were enrolled.
Report a problemFND-2957270902

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT01625520

SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer

Federico II Universityn = 19Feb 2012 to Mar 2016 (primary)

Medullary Thyroid Cancer

Trial page ClinicalTrials.govUpdated 25 Apr 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.